Key result
VKAs maintain recommended TTR in only 35% of non-valvular AF patients.
Why the study?
Non-valvular AF is a major cause of stroke, heart failure, and cardiovascular morbidity, but time in therapeutic range on vitamin K antagonists in the delta region required evaluation.
What proportion of patients with non-valvular atrial fibrillation on Vitamin K antagonists in the delta region achieve adequate time in therapeutic range (TTR)?
Observational (n=100)
What proportion of patients with non-valvular atrial fibrillation on Vitamin K antagonists in the delta region achieve adequate time in therapeutic range (TTR)?
Answers are grounded in this paper and cite their sources.
A significant proportion of patients with non-valvular AF on Vitamin K antagonists in the delta region have suboptimal anticoagulant control, highlighting the need for improved management or alternative therapies.
Background: Non-valvular atrial fibrillation (AF) is the most common cardiac arrhythmia with a prevalence as high as 1.5±2.0% in the general population. This arrhythmia remains one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity in the world. The aim of study was to evaluation of the patients in delta region who have non-valvular AF and on oral anticoagulation with Vitamin K antagonist as regard the time they spend within therapeutic range. Patients and Methods: A total of 100 patients were included in this study for evaluation of the patients in delta region who have non-valvular AF and on oral anticoagulation with Vitamin K antagonist as regard the time they spend within therapeutic range. Results: Our study showed that only 35% achieved the recommended TTR (percent time in therapeutic range) above 60% from studied risk factors, none showed statistical significance. Conclusions: The quality of anticoagulant control was lower that reported in European countries with a significant proportion of patients had TTR below 60%.
No takes yet. Share an insight, caveat, or question.
Aal et al. (2021) conducted an observational in Non-valvular atrial fibrillation (n=100). Vitamin K antagonist was evaluated on Time in therapeutic range (TTR) above 60%. Among patients with non-valvular atrial fibrillation on Vitamin K antagonists, only 35% achieved the recommended time in therapeutic range above 60%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: